Journal of Pediatric Perspectives

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

News

Retinopathy of Prematurity: Treatment-Needed Patients, Treatment Complications, and Recurrence Rate

Document Type : original article

Authors

1 Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

2 Eye research center, Mashhad University of Medical Sciences

3 Associate Professor, Eye Research Center, Department of Ophthalmology, Mashhad University of Medical Sciences, Mashhad, Iran

4 Eye Research Center, Mashhad university of Medical Sciences

5 Eye Research Center, Mashhad University of Medical Sciences

6 Research Center for Patient Safety, Mashhad University of Medical Sciences, Mashhad, Iran

7 Assistant Professor of Ophthalmology Department of Ophthalmology, School of Medicine Khatam Al Anbiya Hospital Mashhad University of Medical Sciences

8 emamat blv- 17th emamat st- No100- 1th floor-Mashhad-Iran

9 Eye Research Center, Farabi Eye Hospital; Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: The prevalence of Retinopathy of Prematurity (ROP) is rising in Iran. We aimed to evaluate the clinical and demographic characteristics of ROP infants who need treatment, the type of treatment, and the complications in the years 2018 to 2022.
Methods: This is a cross-sectional study. We evaluated the patient’s electronic medical records from 2018 to 2022. The required data was extracted from the registry dataset, including demographics, clinical characteristics of infants who required treatment, and the type and severity of treatment-related complications.
Results: From 10,159 infants referred to the retinopathy of prematurity clinic from the beginning of 2018 to 2022, 5008 subjects (49.29%) were suffering from ROP, among whom 416 (8.3%) patients needed treatment for ROP. The mean ± Standard Deviation (SD) of birth age and birth weight were 28.66 ± 2.24 weeks and 1227.24 ± 375.97 grams. While most of our patients (742 eyes, 96.4%) underwent Intravitreal Bevacizumab (IVB) injection as the treatment modality, laser photocoagulation was performed for 25 eyes. Four eyes received pars plana vitrectomy treatment. The recurrent disease occurred in 23 patients (44 eyes). Birth age, birth weight, and the time of oxygen therapy were significantly different between the treatment responders and the neonates who experienced the recurrent disease.
Conclusion: In this study, we showed that the birth age and weight of neonates who experienced a relapse were significantly lower. Besides, the results of treatment with IVB injection were satisfactory, with a relatively low recurrence rate and minimal complications.

Keywords

References

  1.  

    1. Smith LE, editor Pathogenesis of retinopathy of prematurity. Seminars in neonatology; 2003: Elsevier.
    2. Smith LE. Pathogenesis of retinopathy of prematurity. Growth hormone & IGF research. 2004; 14:140-4.
    3. Quimson SK. Retinopathy of prematurity: pathogenesis and current treatment options. Neonatal Network. 2015; 34(5):284-7.
    4. Chiang MF, Quinn GE, Fielder AR, Ostmo SR, Chan RP, Berrocal A, Binenbaum G, Blair M, Campbell JP, Capone Jr A, Chen Y, Dai S, Ells A, Fleck BW, Good WV, Hartnett ME, Holmstrom G, Kusaka S, Kychenthal A, Lepore D, Lorenz B, Martinez-Castellanos MA, Özdek S, Ademola-Popoola D, Reynolds JD, Shah PK, Shapiro M, Stahl A, Toth C, Vinekar A, Visser L, Wallace DK, Wu WC, Zhao P, Zin A. International classification of retinopathy of prematurity. Ophthalmology. 2021; 128(10):e51-e68.
    5. Campbell JP, Ryan MC, Lore E, Tian P, Ostmo S, Jonas K, Paul Chan RV, Chiang MF; Imaging & Informatics in Retinopathy of Prematurity Research Consortium. Diagnostic discrepancies in retinopathy of prematurity classification. Ophthalmology. 2016; 123(8):1795-801.
    6. Palmer EA. Results of a US randomized clinical trial of cryotherapy for ROP (CRYO-ROP). Documenta Ophthalmologica. 1990; 74:245-51.
    7. Good WV, Hardy RJ. The multicenter study of Early Treatment for Retinopathy of Prematurity (ETROP). Ophthalmology. 2001; 108(6):1013-4.
    8. Good WV, Group ETfRoPC. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Transactions of the American Ophthalmological Society. 2004; 102:233.
    9. Moshfeghi DM, Berrocal AM. Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice. Ophthalmology. 2011; 118(7):1227-8.
    10. Blair M, Shapiro MJ. Bevacizumab for ROP. Ophthalmology. 2012; 119(2):431-2.
    11. Kennedy KA, Mintz-Hittner HA, Group B-RC. Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. Journal of American Association for Pediatric Ophthalmology and Strabismus. 2018; 22(1):61-5. e1.
    12. Wallace DK, Wu KY. Current and future trends in treatment of severe retinopathy of prematurity. Clinics in perinatology. 2013; 40(2):297-310.
    13. Mueller B, Salchow D, Waffenschmidt E, Joussen A, Schmalisch G, Czernik C, Bührer CH, Schunk KU, Girschick HJ, Winterhalter S. Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. British Journal of Ophthalmology. 2017; 101(3):365-70.
    14. Azami M, Jaafari Z, Rahmati S, Farahani AD, Badfar G. Prevalence and risk factors of retinopathy of prematurity in Iran: a systematic review and meta-analysis. BMC ophthalmology. 2018; 18(1):1-14.
    15. Zarei M, Bazvand F, Ebrahimiadib N, Roohipoor R, Karkhaneh R, Dastjani AF, Imani Fouladi M, Riazi Esfahani M, Khodabande A, Davoudi S, Ghasemi H, Modjtahedi BS. Prevalence and risk factors of retinopathy of prematurity in Iran. Journal of ophthalmic & vision research. 2019; 14(3):291.
    16. Lemaître D, Barjol A, Abdelmassih Y, Farnoux C, Martin GC, Metge F, Chapron T, Caputo G. Treatment outside the recommended guidelines for retinopathy of prematurity (ROP): Prevalence, characteristics, and issues. Journal of Clinical Medicine. 2022; 11(1):39.
    17. Gupta MP, Chan RP, Anzures R, Ostmo S, Jonas K, Chiang MF, Gupta MP, Paul Chan RV, Anzures R, Ostmo S, Jonas K, Chiang MF; Imaging & Informatics in ROP Research Consortium. Practice patterns in retinopathy of prematurity treatment for disease milder than recommended by guidelines. American journal of ophthalmology. 2016; 163:1-10.
    18. Hård AL, Hellström A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment–a review. Acta paediatrica. 2011; 100(12):1523-7.
    19. Chan-Ling T, Gole GA, Quinn GE, Adamson SJ, Darlow BA. Pathophysiology, screening and treatment of ROP: a multi-disciplinary perspective. Progress in retinal and eye research. 2018; 62:77-119.
    20. Ryu J. New aspects on the treatment of retinopathy of prematurity: Currently available therapies and emerging novel therapeutics. International Journal of Molecular Sciences. 2022; 23(15):8529.
    21. Sen P, Wu W-C, Chandra P, Vinekar A, Manchegowda PT, Bhende P. Retinopathy of prematurity treatment: Asian perspectives. Eye. 2020; 34(4):632-42.
    22. Prakalapakorn SG, Greenberg L, Edwards EM, Ehret DE. Trends in retinopathy of prematurity screening and treatment: 2008–2018. Pediatrics. 2021; 147(6).
    23. Shukla R, Murthy G, Gilbert C, Vidyadhar B, Mukpalkar S. Operational guidelines for ROP in India: a summary. Indian Journal of Ophthalmology. 2020; 68(Suppl 1):S108.
    24. Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, Li J, Liew M, Maier R, Zhu Q, Marlow N. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomized controlled trial. The Lancet. 2019; 394(10208):1551-9.
    25. Chen Y, Wang S, Chen S, Chen X, Han L, Zhong Q, Zhang K. Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study. BMC ophthalmology. 2022; 22(1):1-7.
    26. Mirghorbani M, Rashidinia A, Yaseri M, Zarei M, Khojasteh H, Bazvand F, Modjtahedi BS. Progression of retinal vascularization after intravitreal anti-vascular-endothelial growth factor therapy in retinopathy of prematurity. International Journal of Retina and Vitreous. 2022; 8(1):13.
    27. Bavinger JC, Yu Y, VanderBeek BL. The Comparative Risk of Endophthalmitis Following Intravitreal Injection with Bevacizumab, Aflibercept, and Ranibizumab. Retina (Philadelphia, Pa). 2019; 39(10):2004.
    28. Group ETfRoPC. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Archives of Ophthalmology (Chicago, Ill: 1960). 2003; 121(12):1684-94.
    29. Barnett JM, Hubbard GB. Complications of retinopathy of prematurity treatment. Current opinion in ophthalmology. 2021; 32(5):475-81.
    30. Sampat KM, Garg SJ. Complications of intravitreal injections. Current opinion in ophthalmology. 2010; 21(3):178-83.

     

Journal of Pediatric Perspectives
Volume 11, Issue 8
August 2023
Pages 18104-18111
Files
Share
How to cite
Statistics